Cargando…
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
BACKGROUND: Real-world disease models spanning multiple treatment lines can provide insight into the (cost) effectiveness of treatment sequences in clinical practice. OBJECTIVE: Our objective was to explore whether a disease model based solely on real-world data (RWD) could be used to estimate the e...
Autores principales: | Holleman, Marscha S., Huygens, Simone A., Al, Maiwenn J., Kuppen, Malou C. P., Westgeest, Hans M., van den Bergh, Alfonsus C. M., Bergman, Andries M., van den Eertwegh, Alfonsus J. M., Hendriks, Mathijs P., Lampe, Menuhin I., Mehra, Niven, van Moorselaar, Reindert J. A., van Oort, Inge M., Somford, Diederik M., de Wit, Ronald, van de Wouw, Agnes J., Gerritsen, Winald R., Groot, Carin A. Uyl-de |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114194/ https://www.ncbi.nlm.nih.gov/pubmed/35314962 http://dx.doi.org/10.1007/s40801-022-00294-7 |
Ejemplares similares
-
Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012) -
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
por: Holleman, Marscha S, et al.
Publicado: (2019) -
A clinician’s guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer
por: Veen, Kevin M., et al.
Publicado: (2020) -
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019) -
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020)